Neurofibromatosis type 1-plexiform neurofibromas: Integrating treatment across pediatric and adult populations
Open Access
- 5 February 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (4) , 847-863
Abstract
Plexiform neurofibromas (PNs) are a hallmark of neurofibromatosis type 1 (NF1), affecting ∼50% of individuals with the condition. Originating from Schwann cells and other peripheral nerve sheath components, these tumors can cause significant morbidity, including functional impairment, diminished health-related quality of life, chronic pain, and malignant transformation. Managing NF1-PNs is challenging because of disease variability, differing growth rates, and age-related differences in clinical presentation and treatment tolerability. This review examines current therapeutic strategies, including surgery, medical therapies, and emerging treatments, emphasizing individualized care. Highlighted here is the need for age-specific treatment planning, particularly as disease progression, comorbidities, and side-effect profiles differ between pediatric and adult patients. Optimizing outcomes requires personalized surveillance and coordinated multidisciplinary management across all age groups. While MEK inhibitors (MEKi) provide therapeutic benefit, their long-term efficacy and safety, particularly in pediatric patients who may receive these agents for extended periods, warrant further investigation. Additionally, adult patients face unique comorbidities that may complicate therapy. Superficial PNs and potential MEK inhibitor resistance remain underexplored. Growing interest in combination therapies and adjuvant strategies may improve outcomes. Ongoing research is crucial to personalize treatment regimens, to identify effective combinations, and to refine surveillance protocols, ultimately enhancing long-term quality of life for individuals living with NF1-PN.Keywords
Funding Information
- Springworks Therapeutics, Inc
- KGaA
- Darmstadt
This publication has 139 references indexed in Scilit:
- The burden of epilepsy and unmet need in people with focal seizuresBrain and Behavior, 2022
- Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional studyPediatric Blood & Cancer, 2019
- Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18F]FDG‐PET imaging. Is it of value in asymptomatic patients?Pediatric Blood & Cancer, 2017
- Using a qualitative approach to conceptualize concerns of patients with neurofibromatosis type 1 associated plexiform neurofibromas (pNF) across the lifespanAmerican Journal of Medical Genetics Part A, 2016
- Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social‐emotional functioning, and quality of lifeAmerican Journal of Medical Genetics Part A, 2015
- 18‐fluorodeoxyglucose‐positron emission tomography (FDG‐PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST)Pediatric Blood & Cancer, 2012
- Malignant peripheral nerve sheath tumorsCancer, 2006
- MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1Neuroradiology, 2006
- MR imaging of abdominopelvic involvement in neurofibromatosis type 1: a review of 43 patientsPediatric Radiology, 2004
- Plexiform neurofibromasAmerican Journal of Medical Genetics, 1999